Pharmacological inhibition of FASN by Orlistat impedes EGFR palmitoylation, enhances its ubiquitination, and suppresses TKI‐resistant EGFR mutant NSCLC cell growth. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.